Nektar Therapeutics (NASDAQ:NKTR) had its price objective hoisted by Jefferies Group from $2.12 to $88.00 in a report issued on Tuesday morning, The Fly reports. Jefferies Group currently has a buy rating on the biopharmaceutical company’s stock. Jefferies Group also issued estimates for Nektar Therapeutics’ Q4 2017 earnings at ($0.43) EPS, FY2017 earnings at ($0.84) EPS, FY2018 earnings at ($0.82) EPS, FY2019 earnings at ($1.01) EPS, FY2020 earnings at ($0.77) EPS, FY2021 earnings at ($0.67) EPS and FY2022 earnings at ($0.67) EPS.
NKTR has been the topic of a number of other reports. Canaccord Genuity Group raised their price target on shares of Nektar Therapeutics from $35.00 to $50.00 and gave the company a buy rating in a report on Wednesday, November 15th. Cowen assumed coverage on shares of Nektar Therapeutics in a report on Tuesday, November 7th. They issued an outperform rating on the stock. Canaccord Genuity assumed coverage on shares of Nektar Therapeutics in a report on Thursday, November 9th. They issued a buy rating and a $35.00 price target on the stock. Roth Capital set a $45.00 price target on shares of Nektar Therapeutics and gave the company a buy rating in a report on Monday, November 13th. Finally, Zacks Investment Research cut shares of Nektar Therapeutics from a hold rating to a sell rating in a report on Tuesday, January 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $42.50.
Shares of Nektar Therapeutics (NASDAQ:NKTR) opened at $71.59 on Tuesday. Nektar Therapeutics has a 1-year low of $11.41 and a 1-year high of $75.33. The firm has a market cap of $11,500.00, a PE ratio of -100.83 and a beta of 1.81. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99.
Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.16. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The business had revenue of $152.90 million for the quarter, compared to analysts’ expectations of $126.50 million. During the same period last year, the business earned ($0.32) EPS. The company’s revenue was up 321.2% compared to the same quarter last year. sell-side analysts predict that Nektar Therapeutics will post -0.76 earnings per share for the current fiscal year.
In related news, CEO Howard W. Robin sold 83,333 shares of Nektar Therapeutics stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $55.69, for a total value of $4,640,814.77. Following the completion of the sale, the chief executive officer now directly owns 272,768 shares in the company, valued at approximately $15,190,449.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher A. Kuebler sold 30,000 shares of Nektar Therapeutics stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $58.66, for a total transaction of $1,759,800.00. Following the completion of the sale, the director now owns 70,500 shares of the company’s stock, valued at $4,135,530. The disclosure for this sale can be found here. Insiders sold a total of 614,017 shares of company stock valued at $20,587,527 over the last quarter. 6.10% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of NKTR. Schwab Charles Investment Management Inc. raised its position in Nektar Therapeutics by 3.4% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 654,847 shares of the biopharmaceutical company’s stock worth $12,803,000 after buying an additional 21,250 shares during the last quarter. Prudential Financial Inc. raised its position in Nektar Therapeutics by 1.1% during the 2nd quarter. Prudential Financial Inc. now owns 265,153 shares of the biopharmaceutical company’s stock worth $5,184,000 after buying an additional 2,910 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Nektar Therapeutics by 14.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 692 shares during the last quarter. Swiss National Bank raised its position in Nektar Therapeutics by 1.5% during the 2nd quarter. Swiss National Bank now owns 255,800 shares of the biopharmaceutical company’s stock worth $5,001,000 after buying an additional 3,900 shares during the last quarter. Finally, Alliancebernstein L.P. raised its position in Nektar Therapeutics by 10.6% during the 2nd quarter. Alliancebernstein L.P. now owns 231,237 shares of the biopharmaceutical company’s stock worth $4,521,000 after buying an additional 22,100 shares during the last quarter. 96.01% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Jefferies Group Raises Nektar Therapeutics (NKTR) Price Target to $88.00” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/20/jefferies-group-raises-nektar-therapeutics-nktr-price-target-to-88-00.html.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.